Arcutis Biotherapeutics, Inc. (“Arcutis” or the ‘Company”) (NASDAQ: ARQT) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. The Company’s lead product, ZORYVE, is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE is FDA-approved for the treatment of plaque psoriasis and is in late-stage development or regulatory filing status for atopic dermatitis, seborrheic dermatitis and scalp and body psoriasis.